Birchview Capital’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Birchview Capital’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$384K	–	55
2020 Q4	$384K	Hold	20,000	–	–	0.22%	44
2020 Q3	$269K	Hold	20,000	–	–	0.18%	45
2020 Q2	$847K	Hold	20,000	–	–	0.51%	28
2020 Q1	$552K	Hold	20,000	–	–	0.49%	27
2019 Q4	$649K	Hold	20,000	–	–	0.47%	29
2019 Q3	$521K	Hold	20,000	–	–	0.35%	27
2019 Q2	$734K	Hold	20,000	–	–	0.45%	23
2019 Q1	$442K	Hold	20,000	–	–	0.28%	34
2018 Q4	$282K	Hold	20,000	–	–	0.27%	40
2018 Q3	$388K	Buy	+20,000	New	+$408K	0.25%	41

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Birchview Capital's ODT Position: Q1 2021 in Review

Birchview Capital sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2021, closing a stake of 20,000 shares — an estimated $384K sold.

Birchview Capital first reported a position in ODT in Q3 2018 and held it in 10 quarters. The position peaked at $847K in Q2 2020. 83 funds tracked by Wall St. Rank hold ODT as of Q1 2021.

Birchview Capital reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Birchview Capital sold 20,000 Odonate Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $384K.
Birchview Capital first reported a position in Odonate Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
Birchview Capital's Odonate Therapeutics, Inc. Common Stock position peaked at $847K in Q2 2020.
83 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Birchview Capital's 13F filing for Q1 2021, filed 14 May 2021.